Amoxapine

CHEMBL1113 Phase 4 معتمد Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

313.8 g/mol

LogP

2.6

Phase

4

A tetracyclic antidepressant that blocks reuptake of norepinephrine and serotonin while also antagonizing dopamine receptors, giving it both antidepressant and mild antipsychotic properties. It is used to treat depression, particularly when psychotic features are present.

الوزن الجزيئي

313,8000 g/mol

LogP

2,60

TPSA

36,90 Å²

قاعدة ليبينسكي للخمسة

ناجح

آلية العمل

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2

InChI

InChI=1S/C17H16ClN3O/c18-12-5-6-15-13(11-12)17(21-9-7-19-8-10-21)20-14-3-1-2-4-16(14)22-15/h1-6,11,19H,7-10H2

Molecular Formula

C17H16ClN3O

HBD / HBA

1 / 3

الروابط القابلة للدوران

1

الذرات الثقيلة

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

A tetracyclic antidepressant that blocks reuptake of norepinephrine and serotonin while also antagonizing dopamine receptors, giving it both antidepressant and mild antipsychotic properties. It is used to treat depression, particularly when psychotic features are present.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Amoxapine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1113. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 2170. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Amoxapine على PillFYI

البنية

بيانات سريعة

الصيغة الجزيئية: C17H16ClN3O

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.